Skip to main content
SpringerLink
Log in

Endokrinpharmakologie

  • Chapter
Klinische Endokrinologie für Frauenärzte

  • 2471 Accesses

Zusammenfassung

In diesem Kapitel soll die Pharmakologie der für die Therapie in der frauenärztlichen Praxis wichtigsten Hormone und hormonähnlichen synthetischen Substanzen besprochen werden, soweit sie nicht in den klinischen Kapiteln in anderem Zusammenhang angemessen dargestellt ist. Entsprechend ihrer großen praktischen Bedeutung nehmen die Sexualsteroide und ihre synthetischen Abkömmlinge einen breiten Raum ein. Sexualsteroide und ihre Derivate gehören weltweit zu den am häufigsten verschriebenen Medikamenten. Die wichtigsten Indikationsbereiche sind die orale Kontrazeption und die Hormontherapie im Alter. Bei den Sexualsteroiden unterscheidet man nach ihren Hauptwirkungen Östrogene, Androgene und progesteronähnliche Substanzen (Gestagene). Die geschlechtsspezifischen Wirkungen der Sexualsteroide auf die Fortpflanzungsorgane und -funktionen von Frau und Mann sind schon lange bekannt und in ▸ Kap. 1 sowie ▸ Kap. 2 ausführlich besprochen worden. Darüber hinaus ist in ▸ Kap. 2 dargestellt, dass Sexualsteroide auf praktisch alle Organe und Körperfunktionen Auswirkungen haben und auch Nebenerscheinungen auslösen können, deren richtige Deutung praktisch-klinisches Handeln zur Folge hat.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adlercreutz H, Mazur W (1997) Phyto-oestrogens and western diseases. Ann Med 29: 95

    PubMed  CAS  Google Scholar 

  • Ascoli M, Fanelli F, Segaloff DL (2002) The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev 23: 141

    PubMed  CAS  Google Scholar 

  • Barbieri RL, Osathanondh R, Ryan KJ (1981) Danazol inhibition of steroidogenesis in the human corpus luteum. Obstet Gynecol 57: 722

    PubMed  CAS  Google Scholar 

  • Barbieri RL, Speroff L, Walker AM, McPherson K (1999) Therapeutic controversy: the safety of third-generation oral contraceptives. J Clin Endocrinol Metab 84: 1822

    PubMed  CAS  Google Scholar 

  • Barrett-Connor E, Grady D, Sashegyi A et al. (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287: 847–857

    PubMed  CAS  Google Scholar 

  • Barrett-Connor E, Mosca L, Collins P et al. (2006) Raloxifen Use for The Heart (Ruth)Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355: 125

    PubMed  CAS  Google Scholar 

  • Baulieu EE (1985) RU 486: an antiprogestin steroid with contragestive activity in women. In: Baulieu EE, Segal SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, p 1

    Google Scholar 

  • Beral V, Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419

    PubMed  CAS  Google Scholar 

  • Beral V, Million Women Study Collaborators (2005) Endometrial cancer and hormon-replacement therapy in the Million Women Study. Lancet 365: 1543

    PubMed  Google Scholar 

  • Beral V, Million Women Study Collaborators, Bull D, Green J, Reeves G (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703

    PubMed  CAS  Google Scholar 

  • Berry J (2005) Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. Clin Ther 27: 1671

    PubMed  CAS  Google Scholar 

  • Bjarnason NH, Bjarnason K, Haarbo J et al. (1997) Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 82: 1752

    PubMed  CAS  Google Scholar 

  • Bohnet HG, Hanker JP, Schweppe KW, Schneider HP (1981) Changes of prolactin secretion following long-term danazol application. Fertil Steril 36: 725

    PubMed  CAS  Google Scholar 

  • Briggs MH, Briggs M (1971) Effect of oral ethinly estradioll on serum proteins in normal women. Contraception 3: 381

    CAS  Google Scholar 

  • Brodie AM, Njar VC (2000) Aromatase inhibitors and their application in breast cancer treatment. Steroids 65: 171

    PubMed  CAS  Google Scholar 

  • Brogden RN, Goa KL, Faulds D (1993) Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 45: 384

    PubMed  CAS  Google Scholar 

  • Cadepond F, Ulmann A, Baulieu EE (1997) RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 48: 129

    PubMed  CAS  Google Scholar 

  • Castelo-Branco C, Martinez de Osaba MJ, Vanrezc JA et al. (1993) Effects of oophorectomy and hormone replacement therapy on pituitary-gonadal function. Maturitas 17: 101

    PubMed  CAS  Google Scholar 

  • Cheng CK, Leung PCK (2005) Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 26: 283

    PubMed  CAS  Google Scholar 

  • Cho N, Harada M, Imaeda T et al. (1998) Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J Med Chem 41: 4190

    PubMed  CAS  Google Scholar 

  • Chwalisz K, Garg R, Brenner RM et al. (2002) Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Ann N Y Acad Sci 955: 373

    PubMed  CAS  Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713

    Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047

    Google Scholar 

  • Coombes RC, Hall E, Gibson LJ et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081–1092

    PubMed  CAS  Google Scholar 

  • Coombes RC, Kilburn LS, Snowdon CF et al. on behalf of the Intergroup Exemestane Study (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369: 559–570

    PubMed  CAS  Google Scholar 

  • Cumming DC, Yang JC, Rebar RW, Yen SS (1982) Treatment of hirsutism with spironolactone. JAMA 247: 1295

    PubMed  CAS  Google Scholar 

  • Cummings SR, Eckert S, Krueger KA et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281: 2189

    PubMed  CAS  Google Scholar 

  • Cuzick J, Forbes JF, Sestak I et al. (2007) International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer — 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99: 272

    PubMed  CAS  Google Scholar 

  • Darney P (1993) Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multicenter trials. Contraception 48: 323

    PubMed  CAS  Google Scholar 

  • Delmas PD, Bjarnason NH, Mitlak BH et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641

    PubMed  CAS  Google Scholar 

  • Eaker ED, Castelli, WP (1987) Coronary heart disease and its risk factors among women in the Framingham Study. In: Eaker E, Packard B, Wenger N (eds) Coronary heart disease in women. Haymarket Doyma, New York, p 122

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351: 1451

    Google Scholar 

  • EBCTCG, Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351: 1451

    Google Scholar 

  • Edgren RA (1980) Progestagens. In: Givens J (ed) Clinical uses of steroids. Yearbook, Chicago, p 1

    Google Scholar 

  • Edwards DP (2005) Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67: 335

    PubMed  CAS  Google Scholar 

  • Ettinger B, Black DM, Mitlak BH et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 282: 637

    PubMed  CAS  Google Scholar 

  • Ferin J (1972) Pharmacology of the endocrine system and realted drugs. In: Tausk M (ed) Progesterone, progestational drugs and infertility agents. Pergamon Press, Oxford, p 278

    Google Scholar 

  • Fisher B, Costantino JP, Redmond CK et al. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527

    PubMed  CAS  Google Scholar 

  • Flanagan CA, Millar RP, Illing N (1997) Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interactions. Rev Reprod 2: 113

    PubMed  CAS  Google Scholar 

  • Fletcher SW, Colditz GA (2002) Failure of estrogen plus progestin therapy for prevention. JAMA 288: 366

    PubMed  Google Scholar 

  • Fotherby K (1996) Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception 54: 59

    PubMed  CAS  Google Scholar 

  • Gaspard UJ, Lefebvre PJ (1990) Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease. Am J Obstet Gynecol 163: 334

    PubMed  CAS  Google Scholar 

  • Gass EK, Leonhardt SA, Nordeen SK et al. (1998) The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation. Endocrinology 139: 1905

    PubMed  CAS  Google Scholar 

  • Ginsburg J, Prelevic G, Butler D et al. (1995) Clinical experience with tibolone (Livial) over 8 years. Maturitas 21: 71

    PubMed  CAS  Google Scholar 

  • Godsland IF, Crook D, Simpson R et al. (1990) The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323: 1375

    PubMed  CAS  Google Scholar 

  • Gordon T, Kannel WB, Hjortland MC et al. (1978) Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 89: 157

    PubMed  CAS  Google Scholar 

  • Grady D, Herrington D, Bittner V et al. (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA 288: 49

    PubMed  Google Scholar 

  • Gravanis A, Schaison G, George M et al. (1985) Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J Clin Endocrinol Metab 60: 156

    PubMed  CAS  Google Scholar 

  • Green PS, Simpkins JW (2000) Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 18: 347

    PubMed  CAS  Google Scholar 

  • Greiser CM, Greiser EM, Dören M (2007) Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 13: 453

    PubMed  CAS  Google Scholar 

  • Grodstein F, Stampfer MJ, Manson JE et al. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335: 453

    PubMed  CAS  Google Scholar 

  • Grosse R, Roelle S, Herrlich A et al. (2000a) Epidermal growth factor receptor tyrosine kinase mediates Ras activation by gonadotropin-releasing hormone. J Biol Chem 275: 12251

    PubMed  CAS  Google Scholar 

  • Grosse R, Schmid A, Schoneberg T et al. (2000b) Gonadotropin-releasing hormone receptor initiates multiple signaling pathways by exclusively coupling to G(q/11) proteins. J Biol Chem 275: 9193

    PubMed  CAS  Google Scholar 

  • Gruber CJ, Tschugguel W, Schneeberger C, Huber JC (2002) Production and action of estrogens. N Engl J Med 346: 340

    PubMed  CAS  Google Scholar 

  • Gründker C, Gunthert AR, Westphalen S et al. (2002) Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 146: 1

    PubMed  Google Scholar 

  • Gudermann T, Birnbaumer M, Birnbaumer L (1992a) Evidence for dual coupling of the murine luteinizing hormone receptor to adenylyl cyclase and phosphoinositide breakdown and Ca2+ mobilization. Studies with the cloned murine luteinizing hormone receptor expressed in L cells. J Biol Chem 267: 4479

    PubMed  CAS  Google Scholar 

  • Gudermann T, Nichols C, Levy FO et al. (1992b) Ca2+ mobilization by the LH receptor expressed in Xenopus oocytes independent of 3′,5′-cyclic adenosine monophosphate formation: evidence for parallel activation of two signaling pathways. Mol Endocrinol 6: 272

    PubMed  CAS  Google Scholar 

  • Hannaford PC, Croft PR, Kay CR (1994) Oral contraception and stroke. Evidence from the Royal College of General Practitioners’ Oral Contraception Study. Stroke 25: 935

    PubMed  CAS  Google Scholar 

  • Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ (2008) Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 335: 651

    Google Scholar 

  • Haspels AA (1985) Interruption of early pregnancy by an anti-progestational compound, RU 486. Eur J Obstet Gynecol Reprod Biol 20: 169

    PubMed  CAS  Google Scholar 

  • Healy DL (1985) Clinical status of antiprogesterone steroids. Clin Reprod Fertil 3: 277

    PubMed  CAS  Google Scholar 

  • Heinlein CA, Chang C (2002) Androgen receptor (AR) coregulators: an overview. Endocr Rev 23: 175

    PubMed  CAS  Google Scholar 

  • Helgason S, Wilking N, Carlstrom K et al. (1982) A comparative study of the estrogenic effects of tamoxifen and 17 beta-estradiol in postmenopausal women. J Clin Endocrinol Metab 54: 404

    PubMed  CAS  Google Scholar 

  • Herrmann WL, Schindler HM, Wyss R et al. (1985) Effects of the antiprogesterone RU 486 in early pregnancy and during the menstrual cycle. In: Baulieu EE, Segal, SJ (eds) The antiprogestin steroid RU 486 and human fertility control. Plenum, New York, p 179

    Google Scholar 

  • Hol T, Cox MB, Bryant HU et al. (1997) Selective estrogen receptor modulators and postmenopausal women’s health. J Womens Health 6: 523

    PubMed  CAS  Google Scholar 

  • Howell A, Cuzick J, Baum M et al. (2005) ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365: 60

    PubMed  CAS  Google Scholar 

  • Huirne JA, Lambalk CB (2001) Gonadotropin-releasing-hormone-receptor antagonists. Lancet 358: 1793

    PubMed  CAS  Google Scholar 

  • Hulley S, Furberg C, Barrett-Connor E et al. (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 58

    PubMed  CAS  Google Scholar 

  • Hulley S, Grady D, Bush T et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 280: 605

    PubMed  CAS  Google Scholar 

  • International Collaboration of Epidemiological Studies of Cervical Cancer (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16573 women with cervical cancer and 35509 women without cervical cancer from 24 epidemiological studies. Lancet 370: 1609

    Google Scholar 

  • Israel D, Youngkin EQ (1997) Herbal therapies for perimenopausal and menopausal complaints. Pharmacotherapy 17: 970

    PubMed  CAS  Google Scholar 

  • Johansson ED (1971) Depression of the progesterone levels in women treated with synthetic gestagens after ovulation. Acta Endocrinol (Copenh) 68: 779

    CAS  Google Scholar 

  • Jordan VC (2003) Tamoxifen — a most unlikely pioneering medicine. Nat Rev Drug Discov 2: 205

    PubMed  CAS  Google Scholar 

  • Kaiser UB, Conn PM, Chin WW (1997) Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr Rev 18: 46

    PubMed  CAS  Google Scholar 

  • Katkam RR, Gopalkrishnan K, Chwalisz K et al. (1995) Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception. Am J Obstet Gynecol 173: 779

    PubMed  CAS  Google Scholar 

  • Kedar RP, Bourne TH, Powles TJ et al. (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343: 1318

    PubMed  CAS  Google Scholar 

  • Kerin JF, Liu JH, Phillipou G et al. (1985) Evidence for a hypothalamic site of action of clomiphene citrate in women. J Clin Endocrinol Metab 61: 265

    PubMed  CAS  Google Scholar 

  • Kettel LM, Roseff SJ, Berga SL et al. (1993) Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. Fertil Steril 59: 532

    PubMed  CAS  Google Scholar 

  • Kovacs L, Sas M, Resch BA et al. (1984) Termination of very early pregnancy by RU 486 — an antiprogestational compound. Contraception 29: 399

    PubMed  CAS  Google Scholar 

  • Kuhl H (1994) [How oral contraceptives and drugs interact]. Geburtshilfe Frauenheilkd 54: M23

    PubMed  CAS  Google Scholar 

  • Kuhl H, Taubert HD (1987) Das Klimakterium. Pathophysiologie, Klinik, Therapie. Thieme, Stuttgart New York

    Google Scholar 

  • Kuhnz W, Louton T, Humpel M et al. (1995) Influence of high doses of vitamin C on the bioavailability and the serum protein binding of levonorgestrel in women using a combination oral contraceptive. Contraception 51: 111

    PubMed  CAS  Google Scholar 

  • Kuiper GG, Carlsson B, Grandien K et al. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138: 863

    PubMed  CAS  Google Scholar 

  • Kuiper GG, Lemmen JG, Carlsson B et al. (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252

    PubMed  CAS  Google Scholar 

  • Lahmann PH, EPCI Collaborators (2004) Body size and breast cancer: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 111: 762

    PubMed  CAS  Google Scholar 

  • Lauritzen C (1987) Hormonale Kontrazeption. Med wiss Buchreihe, Schering AG, Adam Pharma, Essen

    Google Scholar 

  • Lindheim SR, Presser SC, Ditkoff EC et al. (1993) A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60: 664

    PubMed  CAS  Google Scholar 

  • Lippert TH, Mück AO (1995) Der klinische Stellenwert von Dienogest. In: Teichmann AT (Hrsg.) Dienogest — Präklinik und Klinik eines Gestagens. Walter de Gruyter, Berlin New York, S. 261

    Google Scholar 

  • Liu Z, Auboeuf D, Wong J et al. (2002) Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci USA 99: 7940

    PubMed  CAS  Google Scholar 

  • Ludwig M, Nawroth F (2007) Niedrig dosierte Gonadotropinstimulation in der gynäkologischen Praxis. Gyn Endokrinol 4: 223

    Google Scholar 

  • Lunenfeld B (1999) GnRH analogues. The state of the art at the millenium. Parthenon, New York London

    Google Scholar 

  • Mäkela S, Hyder SM, Stancel GM (1999) Environmental estrogens. In: Oettel M, Schillinger E (eds) Handbook of experimental pharmacology. Estrogens and antiestrogens. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Mann BS, Johnson JR, Kelly R et al. (2005) Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res 11: 5671

    PubMed  CAS  Google Scholar 

  • Manson JE, Allison MA, Rossouw JE et al. (2007) Estrogen therapy and coronary-artery calcification. N Engl J Med 356: 2591

    PubMed  CAS  Google Scholar 

  • Marchbanks PA, McDonald JA, Wilson HG et al. (2002) Oral contraceptives and the risk of breast cancer. N Engl J Med 346: 2025

    PubMed  CAS  Google Scholar 

  • McArdle CA, Franklin J, Green L et al. (2002) Signalling, cycling and desensitisation of gonadotropin-releasing hormone receptors. J Endocrinol 173: 1

    PubMed  CAS  Google Scholar 

  • McDonnell DP, Chang CY, Norris JD (2001) Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM. Ann N Y Acad Sci 949: 16

    PubMed  CAS  Google Scholar 

  • McDonnell DP, Norris JD (2002) Connections and regulation of the human estrogen receptor. Science 296: 1642

    PubMed  CAS  Google Scholar 

  • Meade TW (1982) Oral contraceptives, clotting factors, and thrombosis. Am J Obstet Gynecol 142: 758

    PubMed  CAS  Google Scholar 

  • Millar R, Lowe S, Conklin D et al. (2001) A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci USA 98: 9636

    PubMed  CAS  Google Scholar 

  • Millar RP (2005) GnRHs and GnRH receptors. Anim Reprod Sci 88: 5

    PubMed  CAS  Google Scholar 

  • Millar RP, Lu Z-L, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR (2004) Gonadotropin-releasing hormone receptors. Endocr Rev 25: 235

    PubMed  CAS  Google Scholar 

  • Mills JL, Simpson JL, Rhoads GG et al. (1990) Risk of neural tube defects in relation to maternal fertility and fertility drug use. Lancet 336: 103

    PubMed  CAS  Google Scholar 

  • Mochtar M, Van der Veen F, Ziech M, van Wely M (2007) Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 18: CD005070

    Google Scholar 

  • Moguilewsky M, Philibert D (1984) RU 38486: potent antiglucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by an impaired activation. J Steroid Biochem 20: 271

    PubMed  CAS  Google Scholar 

  • Morales L, Neven P, Paridaens R (2005) Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 17: 559

    PubMed  CAS  Google Scholar 

  • Mueck AO, Seeger H (2007) Kardiovaskuläre Risiken unter HRT in der Postmenopause. Gyn Endocrinol 5: 120

    CAS  Google Scholar 

  • Murkies AL, Wilcox G, Davis SR (1998) Clinical review 92: phytoestrogens. J Clin Endocrinol Metab 83: 297

    PubMed  CAS  Google Scholar 

  • Negro-Vilar A (1999) Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 84: 3459

    PubMed  CAS  Google Scholar 

  • Neill JD, Duck LW, Sellers JC et al. (2001) A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. Biochem Biophys Res Commun 282: 1012

    PubMed  CAS  Google Scholar 

  • Nilsson B, Sodergard R, Damber MG et al. (1983) Free testosterone levels during danazol therapy. Fertil Steril 39: 505

    PubMed  CAS  Google Scholar 

  • Norris JD, Chang, C, McDonnell DP (2001) Estrogen receptor-cofactor interactions as targets for novel drug discovery. In: Schlichting I, Egner U (eds) Data mining in structural biology. Springer, Berlin Heidelberg New York Tokyo, p 181; Ernst Schering Research Foundation Workshop 34

    Google Scholar 

  • Nurwakagari P, Breit A, Hess C et al. (2007) A conformational contribution of the luteinizing hormone-receptor ectodomain to receptor activation. J Mol Endocrinol 38: 259

    PubMed  CAS  Google Scholar 

  • Perez Mayorga M, Gromoll J, Behre HM et al. (2000) Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab 85: 3365

    Google Scholar 

  • Pierce KL, Premont RT, Lefkowitz RJ (2002) Signalling: seven-transmembrane receptors. Nat Rev Mol Cell Biol 3: 639

    PubMed  CAS  Google Scholar 

  • Pike MC, Peters RK, Cozen W et al. (1997) Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89: 1110

    PubMed  CAS  Google Scholar 

  • Pines A, Fisman EZ, Drory Y et al. (1998) The effects of sublingual estradiol on left ventricular function at rest and exercise in postmenopausal women: an echocardiographic assessment. Menopause 5: 79

    PubMed  CAS  Google Scholar 

  • Polderman KH, Stehouwer CD, van Kamp GJ et al. (1993) Influence of sex hormones on plasma endothelin levels. Ann Intern Med 118: 429

    PubMed  CAS  Google Scholar 

  • Porter JB, Jick H, Walker AM (1987) Mortality among oral contraceptive users. Obstet Gynecol 70: 29

    PubMed  CAS  Google Scholar 

  • Psaty BM, Heckbert SR, Atkins D et al. (1994) The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 154: 1333

    PubMed  CAS  Google Scholar 

  • Ravdin PM, Cronin KA, Howlander N et al. (2007) The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 356: 1670

    PubMed  CAS  Google Scholar 

  • Rebar RW, Zeserson K (1991) Characteristics of the new progestogens in combination oral contraceptives. Contraception 44: 1

    PubMed  CAS  Google Scholar 

  • Rigg I A, Hermann H, Yen SS (1978) Absorption of estrogens from vaginal creams. N Engl J Med 298: 195

    PubMed  CAS  Google Scholar 

  • Roelle S, Grosse R, Aigner A, Krell HW, Czubayko F, Gudermann T (2003) Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. J Biol Chem 278: 47307

    PubMed  CAS  Google Scholar 

  • Ross LA, Alder EM (1995) Tibolone and climacteric symptoms. Maturitas 21: 127

    PubMed  CAS  Google Scholar 

  • Rossouw JE, Prentice RL, Manson JE et al. (2007) Postmenopausal hormone therapy and reis of cardiovascular disease by age and years since menopause. JAMA 297: 1465

    PubMed  CAS  Google Scholar 

  • Runnebaum R, Rabe T (1987) New progestogens in oral contra-ceptives. Am J Obstet Gynecol 157: 1059

    PubMed  CAS  Google Scholar 

  • Sacks FM, Walsh BW (1994) Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 5: 236

    PubMed  CAS  Google Scholar 

  • Schubert W, Cullberg G, Edgar B, Hedner T (1994) Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women. Maturitas 20: 155

    PubMed  CAS  Google Scholar 

  • Schulz A, Bruns K, Henklein P et al. (2000) Requirement of specific intrahelical interactions for stabilizing the inactive conformation of glycoprotein hormone receptors. J Biol Chem 275: 37860

    PubMed  CAS  Google Scholar 

  • Schwabe U, Paffrath D (Hrsg.) (2008) Arzneiverordnungsreport 2007, Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295: 2465

    PubMed  CAS  Google Scholar 

  • Shapiro S, Kelly JP, Rosenberg L et al. (1985) Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 313: 969

    PubMed  CAS  Google Scholar 

  • Shaul PW (2000) Novel role of estrogen receptors in vascular endothelium. Semin Perinatol 24: 70

    PubMed  CAS  Google Scholar 

  • Shen Q, Lin D, Jiang X et al. (1994) Blood pressure changes and hormonal contraceptives. Contraception 50: 131

    PubMed  CAS  Google Scholar 

  • Shoham Z, Zosmer A, Insler V (1991) Early miscarriage and fetal malformations after induction of ovulation (by clomiphene citrate and/or human menotropins), in vitro fertilization, and gamete intrafallopian transfer. Fertil Steril 55: 1

    PubMed  CAS  Google Scholar 

  • Shumaker SA, Legault C, Kuller L et al. (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 291: 2947

    PubMed  CAS  Google Scholar 

  • Siegmund-Schultze N, Zylka-Menhorn V, Leinmüller R, Meyer R (2008) Hormontherapie und Brustkrebs: Ein Blick auf die aktuelle Datenlage. Dtsch Ärztebl 105: C230

    Google Scholar 

  • Simoni M, Gromoll J, Nieschlag E (1997) The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr Rev 18: 739

    PubMed  CAS  Google Scholar 

  • Smith CL, Nawaz Z, O’Malley BW (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11: 657

    PubMed  CAS  Google Scholar 

  • Speroff L (2007) Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought. Menopause 15: 1

    Google Scholar 

  • Speroff L, Glass, RH, Kase NG (1999) Clinical gynecologic endocrinology and infertility, 6th edn. Lippincott Williams & Wilkins, Baltimore/MD, p 1200

    Google Scholar 

  • Spitz IM, Chwalisz K (2000) Progesterone receptor modulators and progesterone antagonists in women’s health. Steroids 65: 807

    PubMed  CAS  Google Scholar 

  • Spitz IM, Coelingh Bennink HJ (2000) Progesterone receptor modulators at the start of a new millennium. Steroids 65: 837

    PubMed  CAS  Google Scholar 

  • Stojilkovic SS, Reinhart J, Catt KJ (1994) Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr Rev 15: 462

    PubMed  CAS  Google Scholar 

  • Szkudlinski MW, Fremont V, Ronin C, Weintraub BD (2002) Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure function relationships. Physiol Rev 82: 473

    PubMed  CAS  Google Scholar 

  • Taubert HD, Kuhl H (1995) Kontrazeption mit Hormonen. Thieme, Stuttgart New York

    Google Scholar 

  • Teichmann AT (1990) Influence of oral contraceptives on drug therapy. Am J Obstet Gynecol 163: 2208

    PubMed  CAS  Google Scholar 

  • Tham DM, Gardner CD, Haskell WL (1998) Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83: 2223

    PubMed  CAS  Google Scholar 

  • Sattin RW, Rubin GL, Wingo PA, Webster LA, Ory HW (1986) The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Oral-contraceptive use and the risk of breast cancer. N Engl J Med 315: 405

    Article  Google Scholar 

  • The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273: 199

    Google Scholar 

  • Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM (2006) Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr Rev 27: 575

    PubMed  CAS  Google Scholar 

  • Turgeon JL, McDonnell DP, Martin KA, Wise PM (2004) Hormone therapy: Physiological complexity belies therapeutic simplicity. Science 304: 1269

    PubMed  CAS  Google Scholar 

  • van den Bemd GJ, Kuiper GG, Pols HA, Van Leeuwen JP (1999) Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochem Biophys Res Commun 261: 1

    Google Scholar 

  • van der Vange N, Kloosterboer HJ, Haspels AA (1987) Effect of seven lowdose combined oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynecol 156: 918

    PubMed  Google Scholar 

  • Venturoli S, Marescalchi O, Colombo FM et al.(1999) A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 84: 1304

    PubMed  CAS  Google Scholar 

  • Vergote I, Abram P (2005) Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol 17: 200

    PubMed  Google Scholar 

  • Victor A, Weiner E, Johansson ED (1976) Sex hormone binding globulin: the carrier protein for d-norgestrel. J Clin Endocrinol Metab 43: 244

    PubMed  CAS  Google Scholar 

  • Viscoli CM, Brass LM, Kernan WN et al. (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345: 1243

    PubMed  CAS  Google Scholar 

  • Vogel VG, Costantino JP, Wickerham DL et al. (2006) National Surgical Adjuvant Breast and Bowel Project (NSABP) Effects of tamoxifen vs raloxifen on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295: 2727

    PubMed  CAS  Google Scholar 

  • Wagner JD, Cefalu WT, Anthony MS et al. (1997) Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Metabolism 46: 698

    PubMed  CAS  Google Scholar 

  • Webster J, Piscitelli G, Polli A et al. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331: 904

    PubMed  CAS  Google Scholar 

  • Wilson PW, Garrison RJ, Castelli WP (1985) Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med 313: 1038

    Article  PubMed  CAS  Google Scholar 

  • Wittmann BM, Sherk A, McDonnell DP (2007) Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res 67: 9549

    PubMed  CAS  Google Scholar 

  • WHI, Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321

    Google Scholar 

  • WHI, Writing Group for the Women’s Health Initiative Investigators (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291: 1701

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Walther-Straub-Institut für Pharmakologie und Toxikologie, Ludwig-Maximilians-Universität München, Goethestraße 33, 80336, München

    Thomas Gudermann Prof. Dr. med.

Authors
  1. Thomas Gudermann Prof. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lokstedter Damm 15, 22453, Hamburg

    Freimut Leidenberger

  2. Abt. für Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitätsklinikum Heidelberg, Voßstraße 9, 69115, Heidelberg

    Thomas Strowitzki

  3. Klinik für Frauenheilkunde und Geburtshilfe der Universität Regensburg am Caritas-Krankenhaus St. Josef, Landshuter Straße 65, 93053, Regensburg

    Olaf Ortmann

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Gudermann, T. (2009). Endokrinpharmakologie. In: Leidenberger, F., Strowitzki, T., Ortmann, O. (eds) Klinische Endokrinologie für Frauenärzte. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-89760-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-89760-6_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-89759-0

  • Online ISBN: 978-3-540-89760-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation